MicroCT for Scanning and Analysis of Mouse Bones

Kim, Yung; Brodt, Michael D.; Tang, S. Y.; Silva, Matthew J.

doi:10.1007/978-1-0716-1028-2_11

Cited by 27 publications

(20 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, we further examined the pathology of the bone structure and the ankle joints after the treatment. Micro-CT is an X-ray imaging method that visualizes bone on a microscopic scale, and it can effectively and accurately assess bone structure [ 44 ]. As seen from Figure 6 A, the bone of the model mouse characterized with a rough surface, joint deformities, and inflammatory erosion.…”

Section: Resultsmentioning

confidence: 99%

Dual-Drug Loaded Separable Microneedles for Efficient Rheumatoid Arthritis Therapy

Shi

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Although the inhibitors of the interleukin-6 receptor (IL-6R) and tumor necrosis factor-α (TNF-α) have achieved a certain success in the clinical treatment of rheumatoid arthritis (RA), great effort should be made to overcome side effects and to improve patient compliance. The present research aimed to address these problems by the co-delivery of tocilizumab (TCZ)—an inhibitor of IL-6R—and an aptamer Apt1-67, which specifically inhibits TNF receptor 1 via separable microneedles (MN). MN were featured with a sustained release of TCZ from needle tips and a rapid release of Apt1-67 from needle bodies by using methacrylate groups grafted hyaluronic acid as the fillings of needle tips and polyvinyl alcohol/polyvinyl pyrrolidone as the fillings of needle bodies. Our results demonstrated that TCZ and Apt1-67 were distributed in MN as expected, and they could be released to the surroundings in the skin. In vivo studies revealed that combined medication via MN (TCZ/Apt1-67@MN) was superior to MN loaded with a single drug. Compared with subcutaneous injection, TCZ/Apt1-67@MN was of great advantage in inhibiting bone erosion and alleviating symptoms of CIA mice. This study not only provides a novel approach for combined medication with different release properties but also supplies a strategy for improving drug efficacy.

show abstract

Section: Resultsmentioning

confidence: 99%

Dual-Drug Loaded Separable Microneedles for Efficient Rheumatoid Arthritis Therapy

Shi

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…In addition, it can also be inferred that the properties of CTC composites are stable and have no side effects in mice since there was no significant immune response and inflammatory reaction in the heart, liver, spleen, lung, kidney, and the muscle tissues adjacent to cancer tissues. Micro-CT scanning is an effective way to evaluate the effect of bone repair (Kim et al, 2021;Oliviero In addition, BV/TV has been used to measure tumorinduced osteolysis (Ohba et al, 2014), we can also find that the value in Table 2 demonstrates decreased trabecular osteolysis and increased BMD in the experimental group, which showed that the material degraded in mice and induced tibial healing, and the bone repairing effects were consistent with our previous study (Cheng et al, 2021), which indicated that our CTC composites and small-molecule inhibitors have good effects for the treatment of mouse osteosarcoma. Therefore, the CTC bio-composites were used to fill the defects caused by amputation, and the results showed the new bone tissues induced by the biomaterials repaired the bone defects very well.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Identification of Small-Molecule Inhibitors for Osteosarcoma Targeted Therapy: Synchronizing In Silico, In Vitro, and In Vivo Analyses

Liu

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Objective: The study aimed to explore a new approach for the treatment of osteosarcoma through combining biomaterials with next-generation small molecule–based targeted therapy.Methods: The model of osteosarcoma was established by 4-hydroxyaminoquinoline 1-oxide (4-HAQO) in mice while the collagen-thermosensitive hydrogel–calcium phosphate (CTC) biocomposites were prepared, and the small molecule inhibitors were virtually screened and synthesized. Then, for the osteosarcoma cell line, MG-63 cells were used to validate our bioinformatic findings in vitro, and the mouse osteosarcoma models were treated by combing CTC composites and small-molecule inhibitors after debridement.Results: Five compounds, namely, ZINC150338698, ZINC14768621, ZINC4217203, ZINC169291448, and ZINC85537017, were found in the ZINK database. Finally, ZINC150338698 was selected for chemical synthesis and experimental verification. The results of the MTT assay and Hoechst staining showed that the small-molecule inhibitor ZINC150338698 could significantly induce MG-63 cell death. Furthermore, CTC composites and ZINC150338698 could repair the bone defects well after the debridement of osteosarcoma. In addition, the biomaterials and small-molecule inhibitors have good biocompatibility and biosafety.Conclusion: Our findings not only offer systems biology approach-based drug target identification but also provide new clues for developing novel treatment methods for future osteosarcoma research.

show abstract

“…The bone mineral density (BMD) of the femurs from TBI or sham control mice was determined after dissection, cleaning by removing adherent tissues, fixing in 4% PFA for 12 h, and storage in 100% ethanol. Bones were scanned using micro-CT (Inveon, Siemens, Erlangen, Germany) at a spatial resolution of 55 kVp, 145 mA, 300 ms integration time, and a voxel resolution of 20 µm obtained from 720 views [ 41 ].…”

Section: Methodsmentioning

confidence: 99%

Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice

Zhang

Gao

Yang

et al. 2023

IJMS

View full text Add to dashboard Cite

Accumulating evidence indicates that the increased burden of senescent cells (SCs) in aged organisms plays an important role in many age-associated diseases. The pharmacological elimination of SCs with “senolytics” has been emerging as a new therapy for age-related diseases and extending the healthy lifespan. In the present study, we identified that cycloastragenol (CAG), a secondary metabolite isolated from Astragalus membrananceus, delays age-related symptoms in mice through its senolytic activity against SCs. By screening a series of compounds, we found that CAG selectively kills SCs by inducing SCs apoptosis and that this process is associated with the inhibition of Bcl-2 antiapoptotic family proteins and the PI3K/AKT/mTOR pathway. In addition, CAG treatment also suppressed the development of the senescence-associated secretory phenotype (SASP) in SCs, thereby inhibiting cell migration mediated by the SASP. Furthermore, the administration of CAG for 2 weeks to mice with irradiation-induced aging alleviated the burden of SCs and improved the animals’ age-related physical dysfunction. Overall, our studies demonstrate that CAG is a novel senolytic agent with in vivo activity that has the potential to be used in the treatment of age-related diseases.

show abstract

MicroCT for Scanning and Analysis of Mouse Bones

Cited by 27 publications

References 7 publications

Dual-Drug Loaded Separable Microneedles for Efficient Rheumatoid Arthritis Therapy

Dual-Drug Loaded Separable Microneedles for Efficient Rheumatoid Arthritis Therapy

Identification of Small-Molecule Inhibitors for Osteosarcoma Targeted Therapy: Synchronizing In Silico, In Vitro, and In Vivo Analyses

Cycloastragenol: A Novel Senolytic Agent That Induces Senescent Cell Apoptosis and Restores Physical Function in TBI-Aged Mice

Contact Info

Product

Resources

About